Compare AbCellera Biologics Inc (ABCL) vs Coinbase Global, Inc. (COIN) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
AbCellera Biologics Inc vs Coinbase Global, Inc. — how do they compare? AbCellera Biologics Inc trades at $7.15 (market cap $2.35B), while Coinbase Global, Inc. trades at $159.3 (market cap $43.08B). The key difference: Coinbase Global, Inc. is far larger — about 18.3× AbCellera Biologics Inc's market cap, and AbCellera Biologics Inc is trading nearer its 52-week high, Coinbase Global, Inc. nearer its low. Which is the better fit depends on your goals.
| ABCL | COIN | |
|---|---|---|
Market Cap | $2.35B | $43.08B |
Sector | Health | Technology |
52-Week High | $8.12 | $419.78 |
52-Week Low | $2.78 | $141.09 |
Enterprise Value | $1.99B | $40.36B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AbCellera Biologics (ABCL) trades at $7.69, down 5.18% today, with a bullish technical signal from moving averages but overbought RSI readings. The company reported a net loss of -$146.41M in 2025, with negative margins, though revenue grew to $75.13M. Recent news highlights a major collaboration with Jazz Pharmaceuticals worth up to $876M, potentially boosting future revenue streams. Analyst consensus is strongly bullish with a $9.67 price target, indicating 25.7% upside.
The outlook hinges on execution of new partnerships and pipeline progress, particularly ABCL635 Phase 2 data expected in Q3 2026. Key risks include persistent cash burn, high valuation multiples despite losses, and biotech sector volatility. Investors should weigh the strong analyst support against fundamental challenges and the stock's current technical overbought condition.
COIN trades at $163.51, down 1.19% over 24 hours, with a bearish technical signal and mixed earnings history. The company reported $7.18B revenue in 2025 with a net income margin of 12.2%, though recent quarters showed misses against EPS expectations. Analyst consensus remains bullish with a $233.08 price target, but cash flow trends indicate potential pressure as operating cash flow declined to $2.4B in 2025 from $2.6B in 2024.
The outlook for COIN hinges on execution amid volatile crypto markets, with 55% of analysts rating it a buy. Key risks include regulatory uncertainty and competitive threats, while institutional adoption growth offers upside. Investors should weigh high valuation multiples against earnings volatility and market sentiment shifts.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About AbCellera Biologics Inc
AbCellera Biologics Inc is a biotechnology company. It develops antibodies to treat infectious diseases and various other types of diseases. The company's AI-powered technology sources, searches, decodes and analyzes antibody responses to engineer new antibody drug candidates for its partners.
Read more on ABCL →About Coinbase Global, Inc.
Coinbase Global, Inc. is a regulated cryptocurrency company that provides customers around the world with a platform for buying, selling, transferring, and storing digital assets. The Company offers a variety of products and services that enable individuals, businesses, and developers to participate in the cryptoeconomy.
Read more on COIN →
